Montelukast%252525252525252525252525252525252525252525252525252525252525252520levocetrizine

# Montelukast/Levocetirizine ## Overview Montelukast is a leukotriene receptor antagonist. Levocetirizine is a second-generation antihistamine. This combination is typically used for allergic rhinitis and chronic urticaria. ## Primary Indications * Allergic rhinitis (seasonal and perennial) * Chronic idiopathic urticaria ## Adult Dosing The recommended dose is montelukast 10 mg orally once daily plus levocetirizine 5 mg orally once daily. ## Pediatric Dosing * **Montelukast:** * Ages 6 months to 5 years: 4 mg orally once daily (chewable tablet) * Ages 6 to 14 years: 5 mg orally once daily (chewable tablet) * Ages 15 years and older: 10 mg orally once daily (tablet) * **Levocetirizine:** * Ages 6 months to less than 12 years: 0.25 mg/kg orally once daily, not to exceed 5 mg per day (oral solution or chewable tablets if available and appropriate based on weight). Dosing for specific age groups is available: * 6 months to 5 years: 1.25 mg orally once daily. * 6 to 11 years: 2.5 mg orally once daily. * Ages 12 years and older: 5 mg orally once daily. * **Combination Product:** Fixed-dose combination products are generally not recommended for children under 12 years of age due to the need for weight-based levocetirizine dosing and age-based montelukast dosing. Prescribers should consult specific product labeling for the most appropriate age and weight bands for available formulations. ## Dose Adjustments * **Hepatic Impairment:** No dose adjustment is typically required for montelukast. For levocetirizine, a starting dose of 2.5 mg once daily is recommended in patients with mild to moderate hepatic impairment. Caution is advised, and dose reduction may be necessary in severe hepatic impairment. * **Renal Impairment:** No dose adjustment is typically required for montelukast. For levocetirizine, dose adjustments are necessary based on creatinine clearance (CrCl): * CrCl 31-50 mL/min: 2.5 mg once daily. * CrCl 11-30 mL/min: 2.5 mg every other day. * CrCl <11 mL/min: 2.5 mg twice weekly (every 3-4 days). * Hemodialysis: 5 mg once daily; administer dose after dialysis. For severe renal impairment requiring dialysis, the dosing recommendations for CrCl <11 mL/min should be followed. ## Contraindications * Hypersensitivity to montelukast, levocetirizine, or any component of the formulation. * Severe renal impairment (for levocetirizine). ## Adverse Effects * **Montelukast:** Headache, abdominal pain, diarrhea, cough, upper respiratory tract infection, fever. Neuropsychiatric events (e.g., depression, suicidal thoughts, hallucinations) have been reported; patients should be monitored and instructed to report any changes in behavior. Churg-Strauss syndrome is a rare but serious adverse effect. * **Levocetirizine:** Somnolence, fatigue, dry mouth, pharyngitis, nausea, vomiting, diarrhea. Paradoxical excitement, insomnia may occur. ## Key Drug Interactions * **CYP1A2, CYP2C9, CYP2C19, CYP3A4 inducers (e.g., rifampin, phenytoin, phenobarbital, carbamazepine):** May decrease montelukast levels, but clinical significance is often minor, and no dose adjustment is usually needed. * **Theophylline:** May increase theophylline levels; monitor theophylline levels if concomitant use is necessary. * **CNS Depressants:** Additive sedative effects with other CNS depressants (e.g., alcohol, benzodiazepines, opioids, sedating antihistamines). Caution advised. * **Alcohol:** May increase the sedative effects of levocetirizine. ## Monitoring * Monitor for signs of neuropsychiatric events with montelukast. * Assess for efficacy in symptom control of allergic rhinitis or urticaria. * Monitor renal function if dose adjustment of levocetirizine is required. ## Clinical Pearls * Montelukast is generally well-tolerated, but neuropsychiatric events require careful patient counseling and monitoring. * Levocetirizine can cause significant somnolence; advise patients to use caution when driving or operating machinery. * Consider alternatives if somnolence is problematic, such as nasal corticosteroids or less sedating antihistamines. * The fixed-dose combination is not available for all age groups and formulations. The decision to use individual agents versus a combination product should be based on patient age, weight, renal function, and prescriber preference, after consulting specific product labeling. *** *Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions.*